Short radiation plus drugs for MSS rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation therapy followed by a combination of chemotherapy, immunotherapy, and a pain-relief medication, compared to the standard approach. It is for people with a certain type of rectal cancer that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has not spread to other parts of your body.
- Your tumor is located within 10 cm of your anal opening.
- Your cancer is a type called 'MSS' or 'pMMR' (a specific genetic feature).
- You are between 18 and 75 years old.
- You have not had any prior chemotherapy or immunotherapy.
- You are generally healthy and able to do daily activities without much help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.